IDAI vs XTLB vs AEYE vs NRXP vs MSFT

For growth investors, Microsoft Corporation (MSFT) is the stronger pick with 14.

9% revenue growth year-over-year, versus -32. 4% for T Stamp Inc. (IDAI). Microsoft Corporation (MSFT) offers the better valuation at 30. 9x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate Microsoft Corporation (MSFT) a "Buy" — based on 81 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Microsoft Corporation (MSFT) delivered a total return of +72.

5%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: MSFT returned +787. 7% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Microsoft Corporation (MSFT) is the lower-risk stock at 0.

89β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 158% more volatile than MSFT relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 130% for T Stamp Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Microsoft Corporation (MSFT) is pulling ahead at 14.

9% versus -32. 4% for T Stamp Inc. (IDAI). On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc. grew EPS 43. 9% year-over-year, compared to 15. 6% for Microsoft Corporation. Over a 3-year CAGR, MSFT leads at 12. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Microsoft Corporation (MSFT) is the more profitable company, earning 36.

1% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 36. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MSFT leads at 45. 6% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, MSFT (0.

8% yield) pays a dividend. IDAI, XTLB, AEYE, NRXP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Microsoft Corporation (MSFT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

89), 0. 8% yield, +787. 7% 10Y return). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MSFT: +787. 7%, NRXP: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IDAI (Technology) and XTLB (Healthcare) and AEYE (Technology) and NRXP (Healthcare) and MSFT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

MSFT pays a dividend while IDAI, XTLB, AEYE, NRXP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.